Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that construction of a new production facility has been completed in Suzhou, Jiangsu, China.

The new production facility in China
The new production facility in China

Historically, Eisai has operated its Suzhou Plant for the manufacturing and packaging of solid preparation products for the local market. The establishment of the new facility is aimed at building up the company's local manufacturing capability in order to handle increasing demand in China for its peripheral neuropathy treatment Methycobal® injection in expectation of sustained future growth in the market. The move is also expected to promote cost reduction through improving production efficiency in the medium-term.

The new facility was built on an approximately 134,000m2 lot in the Suzhou Industrial Park which was newly purchased by Eisai for the construction. It stands two floors aboveground with a total floor space of approximately 5,690m2*. Serving as the company's new base for parenteral manufacturing, the new facility is initially equipped with a production line for Methycobal injection that has the capacity to manufacture an approximate maximum of 60 million ampoules per year. Furthermore, the company intends to expand the role of the new facility in the future to function as a global supply center of injection products for a wider range of markets including the rest of Asia and Latin America.

As the country with the third largest market in the world, Eisai regards China as a major force in driving its global business growth. Strengthening its production system in China through the establishment of this new facility, Eisai seeks to make further contributions to patients by ensuring the stable supply of high-quality products to China and other emerging countries.

  • *
    Total floor space has been revised (January 2018).

Media Inquiries:

Public Relations Department,
Eisai Co., Ltd.